Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Really intrigued for tomorrow’s trading and days following. All heavy sells now clear so hopefully some momentum now.
Great post Dave and the accountant
Ducks are lining up
ALB
Ouz
Thanks for all your research shared Big Dave ............. we're off surely !
theAccountant, same article not behind paywall
https://www.msn.com/en-gb/health/medical/affordable-british-made-covid-drug-could-slash-mortality-rates/ar-BB1dLH0Y?ocid=st
If anyone subscribes to the telegraph, could you post the article on the board. Thanks
https://www.telegraph.co.uk/business/2021/02/17/affordable-british-made-covid-drug-could-slash-mortality-rates/
I am utterly delighted by that RNS. That is all.
Like a true accountant, I have added all the big sells from the last two days and they total 1.1bn shares.
The only way is up now.
Ps - another positive is that there were buyers ready to snap these shares up. Otherwise, it would be concerning.
Good luck all.
128.47k O
16-Sep-21 09:05:02 0.08 160,583,900 Sell* 0.08 0.085 128.47k
Another 2 bigie. Popped up. It’s all done. Only way is up from here
Its a non-core holding and so will be quickly flipped to fund itself. VELA offered cash and shares to buy £2.4m interest, so now SGS gets its full cash entitlement. I wish people would just spend a second on SGSs website and you will see it monetises post Phase II by sublicencing on for Phase III and commercialisation. Its sticking to what it does.
Lets be realistic and as per past RNSs, the commercial discussions started back in June or July and these results are no surprise to AZ. Pfizer and Merck breatheing down AZs neck and everyone trying to get early use approval and secure orders 'subject to' from governments, how long before AZ grabs AZD back? It'll want to put in an early use application to MHRA and secure an order asap.
Because SGS hold AZD1656 from which they will make a sheet tonne of money from. They have no long term need for their Vela shares.
I love that no mention is made of selling the drug but rather commercialiation is the now only route mentioned! Meaning upfront payment and annual recurring sales revenue! 8% to Vela.
SGS will no doubt relinquish a % of their holding in AZD1656 to Astra et Al, but the potential annual revenue could be quiet staggering! GLA
To address the negative point, my thoughts are that SGS is a charity who require immediate cash. In any organisation, cash is king.
2 sides to this…
Positive - SGS, a charity that’s needs money to fund other projects, are out selling all 1.1b shares at 0.08, or so it seems. The stock has been bought presumably by people who know what they’re doing. It doesn’t look like they’re using the money to fund phase 3, which perhaps hints at commercialisation. Some might say we’re a coiled spring now.
The negative - if commercialisation is well progressed and expected to multiply the SP quickly, why did SGS sell everything at a 20% discount to the issue price? They could have just sold some for immediate outlay needs and kept the rest for profit. Maybe they’re not quite as confident as we hope.
I don't think the usual Twitterati got anywhere near those shares that've been sold OTC - direct from SGS to the buyers - then reported to the exchange. It'd be great to see some TR1s - one involving Professor Sir Chris Evans at EML and Igraine bulking up would be immense.
This is of no surprise, remember this clue in the RNS on 09/09: “ In light of the encouraging trial results, St George Street Capital will immediately start to undertake commercial discussions with potential licensees and/or fundraise for further clinical trials to investigate AZD1656 in a larger study.”
Great news and it can only be encouraging going forward. Onwards and upwards….starts tomorrow!
3 days! You might miss the bus
77.08k X2. Printed
Excellent news !
I am of the view discussions are well progressed and framework in place pending the final report.
The 9 Jul RNS stated At this time, SGS and Excalibur Medicines Ltd ("EML") have begun the process of progressing commercialisation plans, subject to the trial data being successful.
imo
@Ian
Good post! To the point!
I have premium bonds. They are there if i need some cash I can always access them. Was thinking of cashing them and puting the money into VELA. I might do it very soon but it takes few days to get the money! Let's See!
Be interesting to know what wait we’ve got now. Got to think/hope that at least some ‘subject to’ deal is close
great comment ian
Right, so 7% of VELA just changed hands less than a week after the RNS and SGS gets an immediate massive cash injection and you see that as bad news? SGSs treasury hardly saw a minority interest in a AIM tiddler as a strategic holding.
We've got further evidence thresholds in the trial were met otherwise SGS would've been locked in and again, confirmation commercial deal is under negotiation. Who long before AZ gets this onto emergency use authorisation - Pfizer aims to complete its mid-stage trial this autumn and get an application done in Q4.
Nomura... If you don't understand something so simple, then you should think twice about investing in share's, perhaps premium bond's would be best for you!! ATB.
nomura
The best thing is you wait and see
Spot on Star. This has got very intriguing. Seems to be a plethora of pharmas delivering RNSs today. I suspect some of them are about partnerships between themselves.
Further investors will see this as a great entry point. Tick tock ....